7th Partnering with ACOs Summit

The transition from fee-for-service to value-based reimbursement has altered not only internal treatment procedures, but also external relationships with drug/product manufacturers and service providers. Healthcare stakeholders require value propositions and risk sharing that are in line with Triple Aim goals. To meet these standards, the life science industry must tailor physician engagement strategies, enhance outcomes and serve pressing needs such as IT, infrastructure and population health projects.

Read More

View Less